Praziquantel Failure in the Treatment ofFasciola hepatica | Zendy

David M. Patrick | Zendy; Judith L. IsaacRenton | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Praziquantel Failure in the Treatment ofFasciola hepatica

Author(s) -

David M. Patrick,

Judith L. IsaacRenton

Publication year - 1990

Publication title -

canadian journal of infectious diseases and medical microbiology

Language(s) - English

Resource type - Journals

eISSN - 1918-1493

pISSN - 1712-9532

DOI - 10.1155/1992/864093

Subject(s) - praziquantel , triclabendazole , pharmacotherapy , medicine , drug , helminthiasis , fasciola hepatica , pharmacology , intensive care medicine , immunology , schistosomiasis , helminths

A case of human fascioliasis is presented in which the patient remained symptomatic after treatment with praziquantel and other agents but eventually responded to bithionol. The difficulties in finding an efficacious and tolerable drug therapy for this condition are reviewed with reference to the life cycle and pathogenesis of the parasite. It is concluded that while bithionol remains the current drug of choice, triclabendazole may play a dominant role in the near future.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research